Author(s): Obadia DL, Daxbacher EL, Jeunon T, Gripp AC
Hidradenitis suppurativa is an inflammatory disease with difficult treatment. Currently, the anti-TNF alfa therapy, with monoclonal antibodies (‘biological therapy’), has been shown as a new alternative. However, clinical trials assessing the efficacy of these drugs to treat hidradenitis suppurativa have not yet been published. A case in which the use of infliximab did not result in significant clinical improvement is described.
Dermatology Journal and/or Publisher
Journal Name: Anais brasileiros de dermatologia
Journal Abbreviation: An Bras Dermatol
Journal Date Published: 2010-03-01
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/20191188
Lasted Revision: 2015-11-19
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).